Perceptive Advisors LLC Boosts Holdings in Repligen Corporation $RGEN

Perceptive Advisors LLC grew its holdings in Repligen Corporation (NASDAQ:RGEN) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 315,541 shares of the biotechnology company’s stock after purchasing an additional 45,113 shares during the quarter. Perceptive Advisors LLC owned 0.56% of Repligen worth $51,705,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 31.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC purchased a new position in shares of Repligen in the third quarter valued at approximately $368,387,000. Holocene Advisors LP boosted its stake in shares of Repligen by 47.0% in the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock valued at $184,077,000 after purchasing an additional 440,290 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Repligen in the fourth quarter valued at approximately $199,176,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Repligen by 21.8% in the third quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock valued at $147,595,000 after purchasing an additional 197,778 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 1.4%

NASDAQ RGEN opened at $133.55 on Thursday. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The stock has a market capitalization of $7.53 billion, a PE ratio of 148.39, a price-to-earnings-growth ratio of 2.54 and a beta of 1.09. The firm has a 50 day moving average of $121.10 and a two-hundred day moving average of $136.86.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the previous year, the business posted $0.39 EPS. The firm’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts expect that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of several recent research reports. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Barclays boosted their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, UBS Group lowered their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.